Therapeutic Potential of IgM-based Bispecific Antibodies for the Treatment of Refractory Autoimmune Disease Patients
Time: 11:30 am
day: Day Two
Details:
- Highlighting the unique potential of IgM antibodies for treatment of autoimmune disease
- Utilizing T cells to drive deep B cell depletion for B cell mediated autoimmune diseases
- Sharing pipeline updates including the ongoing imvotamab (CD20 x CD3) Phase 1b clinical trials